Per E Lonning
Overview
Explore the profile of Per E Lonning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
4671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iversen G, Loeng M, Holth A, Lonning P, Geisler J, Knappskog S
Mol Oncol
. 2025 Mar;
PMID: 40072281
Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic variants in other genes have also been linked to melanoma, most familial...
2.
Nikolaienko O, Anderson G, Chlebowski R, Jung S, Harris H, Knappskog S, et al.
Clin Epigenetics
. 2025 Feb;
17(1):28.
PMID: 39980037
Background: Constitutional BRCA1 epimutations (promoter hypermethylation) are associated with an elevated risk of triple-negative breast cancer and high-grade serous ovarian cancer. While MGMT epimutations are frequent in colon cancer, glioblastoma,...
3.
Hatletvedt N, Engebrethsen C, Geisler J, Geisler S, Aas T, Lonning P, et al.
BMC Cancer
. 2025 Feb;
25(1):308.
PMID: 39979836
Background: Functional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown. Methods:...
4.
Nikolaienko O, Eikesdal H, Ognedal E, Gilje B, Lundgren S, Blix E, et al.
Genome Med
. 2023 Dec;
15(1):104.
PMID: 38053165
Background: Normal cell BRCA1 epimutations have been associated with increased risk of triple-negative breast cancer (TNBC). However, the fraction of TNBCs that may have BRCA1 epimutations as their underlying cause...
5.
Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr O, Lillestol R, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300338.
PMID: 38039432
Purpose: Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC...
6.
Margonis G, Boerner T, Bachet J, Buettner S, Moretto R, Andreatos N, et al.
Ann Surg
. 2022 Dec;
278(3):e540-e548.
PMID: 36453261
Objective: To investigate the clinical implications of BRAF -mutated (mut BRAF ) colorectal liver metastases (CRLMs). Background: The clinical implications of mut BRAF status in CRLMs are largely unknown. Methods:...
7.
Sofiyeva N, Krakstad C, Halle M, OMara T, Romundstad P, Hveem K, et al.
Cancer Med
. 2022 Nov;
12(6):6659-6667.
PMID: 36394079
Background: A common 30 kb deletion affecting the APOBEC3A and APOBEC3B genes has been linked to increased APOBEC activity and APOBEC-related mutational signatures in human cancers. The role of this...
8.
Lonning P, Nikolaienko O, Pan K, Kurian A, Eikesdal H, Pettinger M, et al.
JAMA Oncol
. 2022 Sep;
8(11):1579-1587.
PMID: 36074460
Importance: About 25% of all triple-negative breast cancers (TNBCs) and 10% to 20% of high-grade serous ovarian cancers (HGSOCs) harbor BRCA1 promoter methylation. While constitutional BRCA1 promoter methylation has been...
9.
Batalini F, Gulhan D, Mao V, Tran A, Polak M, Xiong N, et al.
Clin Cancer Res
. 2022 Sep;
28(21):4714-4723.
PMID: 36048535
Purpose: The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method...
10.
Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen G, et al.
Genome Med
. 2022 Aug;
14(1):86.
PMID: 35948919
Background: Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant chemotherapy. Methods: We...